One year after receiving CRISPR gene editing therapy at CHOP, a Delaware County baby is thriving, and doctors want to expand ...

Intellia Therapeutics (NasdaqGM:NTLA) has completed enrollment in its phase 3 HAELO trial of lonvo-z for hereditary angioedema. The FDA has lifted the clinical hold on Intellia’s MAGNITUDE-2 trial for ...

In the world of biopharmaceutical innovation, 2024 will be remembered as CRISPR’s breakout year. In the spring, five patients with sickle cell disease began treatment with Casgevy, the first ...

Gene therapy and gene editing are marvels of modern biotechnology, providing revolutionary techniques for fixing genetic abnormalities. Gene therapy introduces functional genetic material to ...

Study finds CRISPR restores the ability for cancer treatments to attack melanoma cancer cells with precision-guided gene edit that ignores healthy cells Wilmington, DE, OCTOBER 15, 2024 -- In a ...

Crispr Therapeutics (CRSP) is downgraded to "Hold" as current valuation already reflects optimism for CTX310 Phase I results and pipeline progress. Intellia Therapeutics (NTLA) maintains a "Buy" ...

Dr. Mark Pennesi looks on as staff at school's Casey Eye Institute perform the first-ever in vivo CRISPR gene edit procedure for the BRILLIANCE clinical trial in Portland. Kristyna Wentz-Graff/OHSU ...

The company could finally be ready to deliver on years of promise.

Regulatory tailwinds and weak earnings set the stage The FDA's draft guidance to speed approval of genome editing and RNA therapies has put CRISPR Therapeutics (CRSP) in focus, even as the company ...

Gene editing has enormous potential to help feed the world’s growing population, but it’s currently difficult, time-consuming ...